Safety Profiles and Toxicity Management

Dr. Rodriguez reviews historical toxicity profiles from earlier ROS1 inhibitors, noting that crizotinib and entrectinib presented novel side effects including visual field changes preventing night driving due to floaters, along with liver function test (LFT) abnormalities requiring monitoring. Modern generations have moved away from visual side effects but continue showing lab abnormalities that are commonly reported but mostly low-grade and manageable with dose reductions and interruptions without preventing treatment continuation. Gastrointestinal toxicities including nausea and vomiting occur with oral agents, requiring preemptive antiemetic prescriptions and patient partnership for successful management.

Dr. Leal describes repotrectinib toxicity profiles, emphasizing potent ROS1-targeted therapy with CNS activity but problematic CNS side effects. The most common toxicities include dizziness, dysgeusia, and paresthesias that can be difficult to manage, occurring in approximately 30% of patients as grade 3 or higher adverse events. These neurologic side effects require supportive care management, but persistence often necessitates dose reductions and dose holds. Clinical data demonstrates that patients maintaining responses continue benefiting despite dose reductions, though these toxicities impact daily life including work concentration and physical activity capability.

The challenge includes distinguishing treatment-related CNS effects from disease progression in brain-metastatic disease, sometimes requiring additional MRI evaluation. Repotrectinib includes ramp-up dosing to help tolerance development, but side effects still occur frequently requiring dose reductions. Additional toxicities include muscle weakness, particularly problematic in clinical practice, and withdrawal flare phenomena requiring tapering rather than abrupt discontinuation to prevent pain flares.

Dr. Rodriguez describes taletrectinib presenting primarily gastrointestinal toxicity and LFT abnormalities requiring frequent laboratory monitoring during the first 2 months with potential dose interruptions or reductions. Gastrointestinal side effects including nausea and vomiting are manageable with antiemetics and dose modifications, generally not interfering significantly with quality of life despite high reporting rates. Dr. Rotow emphasizes that LFT abnormalities represent the most common toxicity, usually grade 1 or 2, requiring laboratory monitoring for identification and appropriate intervention. Gastrointestinal toxicities have quick onset within the first few days, necessitating preemptive patient education about antiemetics and antidiarrheal medications for home management.